-$1.01 expected earnings per share for KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) this quarter

0

Equity research analysts expect KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Rating) to report ($1.01) earnings per share for the current fiscal quarter, according to Zacks. Zero analysts provided earnings estimates for KalVista Pharmaceuticals. The lowest EPS estimate is ($1.19) and the highest is ($0.81). KalVista Pharmaceuticals reported earnings of ($0.65) per share in the same quarter last year, indicating a negative 55.4% year-over-year growth rate. The company is expected to release its next quarterly earnings report on Monday, January 1.

According to Zacks, analysts expect KalVista Pharmaceuticals to report full year earnings of ($3.45) per share for the current fiscal year, with EPS estimates ranging from ($3.82) to ($3. .19). For next year, analysts expect the company to report earnings of ($3.67) per share, with EPS estimates ranging from ($4.63) to ($2.77). Zacks Investment Research earnings per share averages are an average average based on a survey of sell-side research firms that provide coverage for KalVista Pharmaceuticals.

KalVista Pharmaceuticals (NASDAQ:KALV – Get Rating) last reported quarterly earnings data on Thursday, March 10. The specialty pharmaceutical company reported ($0.92) earnings per share (EPS) for the quarter, missing analyst consensus estimates of ($0.91) by ($0.01).

(A d)

“How to Master the Retirement Trade” by options expert Dave Aquino, will take you step by step through one of the most profitable trading windows out there and guide you to profits!

KALV has been the subject of a number of recent research reports. Zacks Investment Research upgraded shares of KalVista Pharmaceuticals from a “sell” rating to a “hold” rating in a Friday, April 29 research note. HC Wainwright reaffirmed a “buy” rating and issued a target price of $48.00 on shares of KalVista Pharmaceuticals in a Friday, March 11 report. Needham & Company LLC lowered its price target on KalVista Pharmaceuticals shares from $48.00 to $42.00 and set a “buy” rating on the stock in a Friday, March 11 report. Finally, Roth Capital reaffirmed a “buy” rating on KalVista Pharmaceuticals shares in a Tuesday, March 8 report. One research analyst gave the stock a hold rating and four gave the company’s stock a buy rating. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $47.00.

Shares of KALV traded down $0.77 during the midday session on Friday, hitting $11.34. The company’s shares had a trading volume of 6,196 shares, compared to an average volume of 223,383. KalVista Pharmaceuticals has a 1-year low of $10.79 and a 1-year high of $30.70. The company has a market capitalization of $278.28 million, a P/E ratio of -3.75 and a beta of 1.79. The company’s 50-day moving average is $14.76 and its two-hundred-day moving average is $14.72.

In other KalVista Pharmaceuticals news, CEO Thomas Andrew Crockett sold 10,000 shares in a trade dated Wednesday, March 9. The shares were sold at an average price of $17.07, for a total transaction of $170,700.00. The sale was disclosed in a document filed with the SEC, accessible via this link. 6.40% of the shares are currently held by company insiders.

Major investors have recently changed their stake in the company. Monashee Investment Management LLC purchased a new stake in KalVista Pharmaceuticals during Q3 for approximately $2,181,000. Two Sigma Advisers LP increased its equity stake in KalVista Pharmaceuticals by 550.2% in Q3. Two Sigma Advisers LP now owns 120,422 shares of the specialty pharmaceutical company valued at $2,101,000 after purchasing an additional 101,900 shares in the last quarter. Suvretta Capital Management LLC increased its stake in shares of KalVista Pharmaceuticals by 29.6% in the 3rd quarter. Suvretta Capital Management LLC now owns 1,543,284 shares of the specialty pharmaceutical company valued at $26,930,000 after purchasing an additional 352,183 shares in the last quarter. Barclays PLC increased its stake in shares of KalVista Pharmaceuticals by 105.2% in the third quarter. Barclays PLC now owns 10,404 shares of the specialty pharmaceutical company valued at $181,000 after buying an additional 5,335 shares in the last quarter. Finally, Trexquant Investment LP bought a new position in shares of KalVista Pharmaceuticals in Q3 valued at around $334,000.

About KalVista Pharmaceuticals (Get a rating)

KalVista Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, discovers, develops and markets small molecule protease inhibitors for diseases with unmet needs. The Company’s product portfolio includes small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.

Featured Articles

Get a Free Copy of Zacks’ Research Report on KalVista Pharmaceuticals (KALV)

For more information on Zacks Investment Research’s research offerings, visit Zacks.com

Earnings history and estimates for KalVista Pharmaceuticals (NASDAQ: KALV)

This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Should you invest $1,000 in KalVista Pharmaceuticals right now?

Before you consider KalVista Pharmaceuticals, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and KalVista Pharmaceuticals wasn’t on the list.

Although KalVista Pharmaceuticals currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here

Share.

Comments are closed.